KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Change in Accured Expenses (2021 - 2025)

Bristol Myers Squibb (BMY) has disclosed Change in Accured Expenses for 5 consecutive years, with -$2.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 492.1% to -$2.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$441.0 million, a 129.72% decrease, with the full-year FY2025 number at -$441.0 million, down 129.72% from a year prior.
  • Change in Accured Expenses was -$2.4 billion for Q4 2025 at Bristol Myers Squibb, down from $1.7 billion in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.8 billion in Q3 2024 to a low of -$2.4 billion in Q4 2025.
  • A 5-year average of $161.8 million and a median of $88.0 million in 2021 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 141.86% in 2022; the steepest drop was 676.92% in 2022.
  • Bristol Myers Squibb's Change in Accured Expenses stood at -$39.0 million in 2021, then crashed by 676.92% to -$303.0 million in 2022, then skyrocketed by 30.36% to -$211.0 million in 2023, then tumbled by 91.94% to -$405.0 million in 2024, then plummeted by 492.1% to -$2.4 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Change in Accured Expenses are -$2.4 billion (Q4 2025), $1.7 billion (Q3 2025), and $881.0 million (Q2 2025).